Phenotypes associated with this allele

• Allele Symbol: Pkn2^{tm1c(KOMP)Wtsi}
• Allele Name: targeted mutation 1c, Wellcome Trust Sanger Institute
• Allele ID: MGI:5911965
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Pkn2^tm1c(KOMP)Wtsi/Pkn2^tm1c(KOMP)Wtsi Tg(Tek-cre)12Flv/0	involves: C3H * C57BL/6 * C57BL/6N	MGI:5912009
cn2	Gt(ROSA)26Sor^tm9(cre/ESR1)Arte/Gt(ROSA)26Sor^+ Pkn2^tm1c(KOMP)Wtsi/Pkn2^tm1c(KOMP)Wtsi	involves: C57BL/6N * C57BL/6NTac	MGI:5912012
cn3	Pkn2^tm1c(KOMP)Wtsi/Pkn2^tm1c(KOMP)Wtsi Tg(Tagln-cre)1Jjl/0	involves: C57BL/6N * FVB/N	MGI:5912010

Genotype
MGI:5912009

cn1

• Allelic Composition: Pkn2^{tm1c(KOMP)Wtsi}/Pkn2^{tm1c(KOMP)Wtsi}; Tg(Tek-cre)12Flv/0
• Genetic Background: involves: C3H * C57BL/6 * C57BL/6N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:229595 )

• viable with no overt vascular phenotypes

Genotype
MGI:5912012

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺; Pkn2^{tm1c(KOMP)Wtsi}/Pkn2^{tm1c(KOMP)Wtsi}
• Genetic Background: involves: C57BL/6N * C57BL/6NTac

embryo

increased embryonic tissue cell apoptosis ( J:229595 )

• following tamoxifen treatment

abnormal embryo turning ( J:229595 )

• tamoxifen treatment at E7.5 results in axial turning defects in most mice at E9.5

abnormal embryo morphology ( J:229595 )

• tamoxifen treatment at E6.5 reproduces the gross phenotypes seen in germline null mice

absent pharyngeal arches ( J:229595 )

• loss of branchial arches following tamoxifen treatment

abnormal mesoderm morphology ( J:229595 )

• decrease in cephalic mesoderm at E10 in embryos treated with tamoxifen at E8.0

abnormal mesenchyme morphology ( J:229595 )

• tamoxifen treatment at E6.5 results in collapse of the mesenchyme

cardiovascular system

abnormal vascular development ( J:229595 )

• vascular disintegration following tamoxifen treatment

hemorrhage ( J:229595 )

• at E10 in embryos treated with tamoxifen at E8.0

cellular

abnormal mitosis ( J:229595 )

• in MEFs tamoxifen treatment results in an accumulation of cells in G1/G0 and loss of S-phase and mitotic cells

decreased mitotic index ( J:229595 )

• in pharyngeal mesodermal cells at E10, 48h past tamoxifen treatment

• however mitotic indices in branchial arch, neural tube, and heart cells are similar to controls

increased embryonic tissue cell apoptosis ( J:229595 )

• following tamoxifen treatment

decreased fibroblast proliferation ( J:229595 )

• reduced MEF cell growth following tamoxifen treatment

• however, tamoxifen treatment of embryonic stem cells does not alter cell growth

craniofacial

absent pharyngeal arches ( J:229595 )

• loss of branchial arches following tamoxifen treatment

Genotype
MGI:5912010

cn3

• Allelic Composition: Pkn2^{tm1c(KOMP)Wtsi}/Pkn2^{tm1c(KOMP)Wtsi}; Tg(Tagln-cre)1Jjl/0
• Genetic Background: involves: C57BL/6N * FVB/N

mortality/aging

lethality, incomplete penetrance ( J:229595 )

cardiovascular system

cardiac hypertrophy ( J:229595 )

• in survivors

respiratory system

overexpanded pulmonary alveolus ( J:229595 )

• alveolar enlargement in survivors

pulmonary fibrosis ( J:229595 )

• in survivors

growth/size/body

cardiac hypertrophy ( J:229595 )

• in survivors